Download PDF
Nervenheilkunde 2014; 33(01/02): 36-41
DOI: 10.1055/s-0038-1627664
Südwestdeutscher Schlaganfalltag
Schattauer GmbH

Was bringen die neuen oralen Medikamente für die Behandlung der Multiplen Sklerose?

What are the new oral medication for the treatment of multiple sclerosis good for?
F. Thömke
1   Fachbereich Neurologie, Klinikum Worms gGmbH
› Author Affiliations
Further Information

Publication History

eingegangen am: 20 August 2013

angenommen am: 01 September 2013

Publication Date:
23 January 2018 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

In neueren Studien konnte gezeigt werden, dass orale Substanzen wie Dimethylfumarat (BG-12), Laquinimod und Teriflunomid bei Patienten mit schubförmig verlaufender Multipler Sklerose (MS) zu einer signifikanten Senkung der Schubrate und signifikant weniger MR-tomografisch nachweisbaren Läsionen führen. Die vorliegende Arbeit fasst die wichtigsten Ergebnisse dieser Studien zusammen und versucht, den Stellenwert dieser Substanzen im Vergleich zu den bisher verfügbaren Basistherapien abzuschätzen.

Summary

Recent studies documented that oral treatment with dimethyl fumarate (BG-12), laquinimod, and teriflunomid significantly reduces relapse rates and neuroradiological outcomes in patients with relapsing-remittent multiple sclerosis. This paper summarizes the results of these studies and tries to assess the status of the new oral treatment options as compared to previous therapies.

Schlüsselwörter

Multiple Sklerose - Laquinimod - Teriflunomid - Dimethylfumarat

Keywords

Multiple sclerosis - laquinimod - terifunomid - dimethyl fumarate
 

  • Literatur

  • 1 Comi G. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366: 1000-9.
    CrossrefPubMedSearch in Google Scholar
  • 2 O’Connor P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-303.
    CrossrefPubMedSearch in Google Scholar
  • 3 Gold R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-107.
    CrossrefPubMedSearch in Google Scholar
  • 4 Fox RJ. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-97.
    CrossrefPubMedSearch in Google Scholar
  • 5 Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368: 1657-58.
    CrossrefPubMedSearch in Google Scholar
  • 6 van Oosten BW. et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368: 1658-9.
    CrossrefPubMedSearch in Google Scholar
  • 7 Arzneimittelkommission der Deutschen Ärzteschaft: “Aus der UAW-Datenbank” - Nokardiose bei Lymphopenie durch Fumaderm®. Dtsch Arztebl. 2013; 110: A-1220.
    Search in Google Scholar
  • 8 Arzneimittelkommission der deutschen Ärzteschaft - “Aus der UAW-Datenbank”: Reversibles Kaposi-Sarkom unter Fumaderm®-assoziierter Lymphozytopenie. Dtsch Arztebl. 2009; 106: A-2380.
    Search in Google Scholar
  • 9 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
    CrossrefPubMedSearch in Google Scholar
  • 10 PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
    CrossrefPubMedSearch in Google Scholar
  • 11 Johnson KP. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-76.
    CrossrefPubMedSearch in Google Scholar